ReviewJournal of experimental & clinical cancer research : CR2016
Patient-derived xenografts: a relevant preclinical model for drug development.
Review in Journal of experimental & clinical cancer research : CR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03871790 (Peptide-based Immunization for Colon- and Pancreas-carcinoma), which is not on this map. Cited by 94 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Peptide-based Immunization for Colon- and Pancreas-carcinoma (PICOP-GLOBAL): An International, Multicenter Protocol
Who cites it
94 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meningioma animal models: a systematic review and meta-analysis.Journal of translational medicine · 2023Pooled it
- Comparison of Cell Line-Derived and Patient-Derived Xenograft Technologies in Oncology (Review).Bulletin of experimental biology and medicine · 2026Article
- Techniques to study chimerism at the tissue level in humanized mice.Veterinary pathology · 2026Article
- Review
- The application of experimental models for the drug discovery for digestive tumors.Molecular cancer · 2026Review
- DSG2-Directed CAR-T Cells Safely and Universally Eliminate Solid Tumors.Research square · 2026Article
- Choosing the right animal model for sarcoma research.Cellular and molecular life sciences : CMLS · 2026Review
- CRISPR-StAR enables high-resolution genetic screening in complex in vivo models.Nature biotechnology · 2025Article
- Silvestrol inhibits nasopharyngeal carcinoma cells and synergizes with CX-5461: Insights from a proteomics study.Molecular and clinical oncology · 2025Article
- Advancing oral squamous cell carcinoma research: the evolving role of patient-derived cell lines, xenografts, and organoid models.3 Biotech · 2025Review
- Prediction of Patient Drug Response via 3D Bioprinted Gastric Cancer Model Utilized Patient-Derived Tissue Laden Tissue-Specific Bioink.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The roles of patient-derived xenograft models and artificial intelligence toward precision medicine.MedComm · 2024Review
- Activating Invasion and Metastasis in Small Cell Lung Cancer: Role of the Tumour Immune Microenvironment and Mechanisms of Vasculogenesis, Epithelial-Mesenchymal Transition, Cell Migration, and Organ Tropism.Cancer reports (Hoboken, N.J.) · 2024Review
- Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft models.Scientific reports · 2024Article
- A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis.Cancer research · 2024Article
- Nanoengineering Solutions for Cancer Therapy: Bridging the Gap between Clinical Practice and Translational Research.Journal of clinical medicine · 2024Article
- SERS in 3D cell models: a powerful tool in cancer research.Chemical Society reviews · 2024Review
- Novel frontiers in urogenital cancers: from molecular bases to preclinical models to tailor personalized treatments in ovarian and prostate cancer patients.Journal of experimental & clinical cancer research : CR · 2024Review
- Orthotopic and metastatic tumour models in preclinical cancer research.Pharmacology & therapeutics · 2024Review
- Tumor Organoid as a Drug Screening Platform for Cancer Research.Current stem cell research & therapy · 2024Review
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identifying appropriate preclinical cancer models remains a major challenge in increasing the efficiency of drug development. A potential strategy to improve patient outcomes could be selecting the 'right' treatment in preclinical studies performed in patient-derived xenografts (PDXs) obtained by direct implants of surgically resected tumours in mice. These models maintain morphological similarities and recapitulate molecular profiling of the original tumours, thus representing a useful tool in evaluating anticancer drug response. In this review, we will present the state-of-art use of PDXs as a reliable strategy to predict clinical findings. The main advantages and limitations will also be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.